Labs (Blood Tests) for TRT – 12 Rules to Live by on Testosterone

Member Access Required

Already a member? Sign In

Timeline

00:00

A lab-focused rule is introduced, separating baseline evaluation from ongoing follow-up once therapy begins. The emphasis stays on clinically meaningful testing that supports safer long-term testosterone use.

01:14

Initial workup labs are framed as primary care foundations, including CBC, fasting metabolic panels, A1c, and lipid testing. Prostate screening with PSA is presented as essential before any hormone changes occur.

02:23

Hormone testing is described as requiring total and free testosterone rather than a total-only approach. High-quality measurement methods are highlighted to avoid misleading results from weaker assays.

04:16

FSH and LH are presented as mandatory to localize the source of low testosterone within the axis. Ultrasensitive estradiol and sex hormone binding globulin are added to interpret hormone fractions accurately.

06:39

Ongoing lab planning shifts toward follow-up intervals tied to dosing half-life and expected pharmacology. Nadir sampling is described as the most useful reference point before the next dose.

08:00

Peak and trough behavior is discussed to explain why overly infrequent dosing can create unstable symptoms. Lower effective dosing and flexible schedules are framed as practical strategies for many men.

11:35

Sex hormone binding globulin is described as only occasionally useful during stable therapy at lower doses. Oral anabolic agents like anavar or winstrol are noted as lowering binding globulin more dramatically.

14:39

CBC monitoring is emphasized because hemoglobin and hematocrit can rise, creating polycythemia concerns. Iron studies are paired with red cell trends so management decisions reflect physiology, not reflex actions.

15:35

PSA follow-up is presented as mandatory because missed monitoring can delay detection of prostate cancer. Rising PSA is framed as requiring evaluation for BPH or prostatitis, not immediate assumptions.

18:02

Secondary monitoring is discussed for broader health, including lipids, blood pressure, and metabolic panels when indicated. Coordination with primary care is emphasized so overall prevention stays covered.

19:45

The closing message encourages men to bring a structured lab list to clinicians and remain engaged in monitoring. Education and consistent follow-up are framed as the best protection for long-term outcomes.

Video Summary

Laboratory planning begins by separating baseline evaluation from ongoing monitoring during testosterone therapy. Baseline testing is framed as essential before any androgen exposure begins for the first time. Core primary care labs include a complete blood count and a fasting metabolic panel for kidney and liver function. Hemoglobin A1c and a lipid panel are highlighted to quantify diabetes risk and cardiovascular risk. Prostate screening starts with a total PSA, because prostate safety is treated as a central priority. Thyroid screening with TSH and reflex free T4 is suggested when fatigue and low libido overlap. Additional baseline items include vitamin D, urinalysis, and hormone measurements that clarify true deficiency.

Total testosterone alone is described as insufficient for a credible diagnosis in many men. Free testosterone measured with high-quality methodology is recommended, including dialysis-based techniques and LC-MS/MS support. Prolactin is included because elevations can mimic androgen deficiency symptoms and are often missed. FSH and LH are labeled mandatory for localization across the hypothalamic, pituitary, and gonadal axis. Estradiol testing is recommended using an ultrasensitive assay rather than a broad total estrogen measurement. Sex hormone binding globulin is used to interpret gaps between total and free testosterone results. Past exposure to anabolic steroids or corticosteroids like prednisone is noted as a factor influencing this axis.

Ongoing monitoring begins after therapy starts, with timing tied to half-life, dosing frequency, and peak and trough behavior. Follow-up total and free testosterone plus ultrasensitive estradiol are suggested around two months after initiation in common regimens. Sampling is advised at the nadir, meaning the low point right before the next dose would occur. Complete blood count with hemoglobin and hematocrit is presented as mandatory because polycythemia can develop on androgens. Iron studies are paired with red cell results so responses like phlebotomy are not used blindly. PSA is emphasized for ongoing prostate oversight, with caution that rising values can reflect cancer, BPH, or prostatitis. Repeated FSH, LH, prolactin, and binding globulin are described as unnecessary once exogenous testosterone suppresses gonadotropins. Secondary surveillance can include lipid trends, blood pressure, and metabolic panels when comorbid disease requires monitoring.

Drug Callouts

Testosterone enanthate

Testosterone enanthate is an injectable testosterone ester with sustained release after intramuscular dosing. It is referenced while criticizing long intervals that create large peaks and troughs.

Testosterone cypionate

Testosterone cypionate is an injectable testosterone ester commonly used for replacement therapy in men. It is mentioned while discussing dosing cadence and nadir timing for lab interpretation.

Sustanon 250

Sustanon 250 is a blend of testosterone esters designed to extend duration of action. It is used as an example where some clinicians dose too infrequently, creating unstable hormone swings.

Prednisone

Prednisone is a systemic corticosteroid used to reduce inflammation in many chronic diseases. It is listed as a prior exposure that can affect the androgen axis and symptom interpretation.

Anavar

Anavar is the common name for oxandrolone, an orally active anabolic steroid. It is mentioned as an oral agent that can strongly lower sex hormone binding globulin.

Winstrol

Winstrol is the common name for stanozolol, an anabolic steroid that can be taken orally. It is referenced as another oral agent associated with marked lowering of binding globulin.

Condition Callouts

Hypogonadism

Hypogonadism is a clinical state where inadequate testosterone production causes symptoms and low measured levels. The discussion stresses pairing symptoms with total and free testosterone plus gonadotropin testing.

Polycythemia

Polycythemia is an abnormal increase in red blood cell concentration that can raise blood viscosity. It is presented as a common issue on androgens that requires CBC and iron study interpretation.

Prostate cancer

Prostate cancer is malignant growth of prostate tissue that can elevate PSA and threaten long-term health. PSA monitoring is emphasized because missed screening can delay detection during testosterone use.

Benign prostatic hyperplasia

Benign prostatic hyperplasia is noncancerous enlargement of the prostate that can raise PSA and urinary symptoms. It is listed as a competing explanation when PSA rises during ongoing monitoring.

Prostatitis

Prostatitis is inflammation of the prostate that can raise PSA and cause pelvic discomfort. It is included as another reason PSA elevation needs careful evaluation rather than assumptions.

Chronic kidney disease

Chronic kidney disease is persistent impairment in kidney function that can affect medication safety and lab planning. Metabolic panels are referenced for men with hypertension or kidney risk factors.

Liver disease

Liver disease is chronic injury to hepatic tissue that can change metabolism and lab surveillance needs. Metabolic panels are discussed as relevant when liver conditions are present in history.

Hypertension

Hypertension is persistent elevation of blood pressure that increases cardiovascular risk over time. Blood pressure is emphasized alongside lipid testing as part of heart safety monitoring.

Depression

Depression is a mood disorder characterized by persistent low mood and impaired motivation. Mental health history is referenced as relevant when interpreting symptoms and hormone fractions.

Asthma

Asthma is a chronic airway inflammatory condition that can require intermittent systemic corticosteroids. Prior prednisone exposure in asthma is noted as a factor that can influence androgen physiology.

Key Takeaways

Baseline evaluation should include CBC, metabolic panel, A1c, lipids, and PSA.
Total and free testosterone with quality assays help avoid misleading results.
FSH, LH, prolactin, and ultrasensitive estradiol clarify diagnosis before therapy.
Follow-up testing should target nadir timing and track hematocrit for polycythemia risk.
PSA trends need interpretation alongside BPH or prostatitis, not only cancer fear.